CHMP endorses Roche’s breast cancer therapy for administration out of clinical settings
Roche has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for updating the European Union (EU) label of Phesgo. This fixed-dose combo of Perjeta (pertuzumab) and Herceptin ( …